Filing Details
- Accession Number:
- 0001209191-12-031713
- Form Type:
- 4/A
- Zero Holdings:
- No
- Publication Time:
- 2012-06-01 17:08:32
- Reporting Period:
- 2012-05-14
- Filing Date:
- 2012-06-01
- Accepted Time:
- 2012-06-01 17:08:32
- Original Submission Date:
- 2012-05-16
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1294596 | Nancy Wysenski | C/O Vertex Pharmaceuticals Incorporated 130 Waverly St Cambridge MA 02139 | Evp, Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2012-05-14 | 179,628 | $64.27 | 32,604 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2012-05-14 | 372 | $65.00 | 32,232 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- Amended to delete a prior footnote that indicated, due to a clerical error by the company, that these transactions were pursuant to a Rule 10b5-1 plan. The Form 144 filed with the SEC in connection with the transactions accurately noted that the sales were not conducted under a Rule 10b5-1 plan.
- Open market sales reported on this line occurred at a weighted average price of $64.27 (range $63.90 to $64.82).
- Ms. Wysenski undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Billionaire Hedge Funds
